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Interactions between tumor cells and tumor microenvironment are considered critical in carcinogenesis, 
tumor invasion and metastasis. To examine transcriptome changes and to explore the relationship 
with tumor microenvironment in canine cutaneous melanocytoma and melanoma, we extracted RNA 
from formalin-fixed, paraffin-embedded (FFPE) specimens and analyzed them by means of RNA-
seq for transcriptional analysis. Melanocytoma and melanoma samples were compared to detect 
differential gene expressions and significant enriched pathways were explored to reveal functional 
relations between differentially expressed genes. The study demonstrated a differential expression 
of 60 genes in melanomas compared to melanocytomas. The differentially expressed genes cluster 
in the extracellular matrix-receptor interaction, protein digestion and absorption, focal adhesion 
and PI3K-Akt (phosphoinositide 3-kinase/protein kinase B) signaling pathways. Genes encoding for 
several collagen proteins were more commonly differentially expressed. Results of the RNA-seq were 
validated by qRT-PCR and protein expression of some target molecules was investigated by means of 
immunohistochemistry. We hypothesize that the developing melanoma actively promotes collagen 
metabolism and extracellular matrix remodeling as well as enhancing cell proliferation and survival 
contributing to disease progression and metastasis. In this study, we also detected unidentified genes 
in human melanoma expression studies and uncover new candidate drug targets for further testing in 
canine melanoma.
Despite recent advances in the understanding of its pathogenesis, melanoma remains the deadliest form of malig-
nant skin tumor in human beings and its annual incidence has increased by more than 60 percent from 1991 to 
2011 (http://www.cancer.gov/research/progress/snapshots/melanoma). No effective therapy is currently avail-
able and tumor-associated mortality is due to metastatic spread to distant sites1. In human medicine, several 
studies have identified different patterns of gene expression in melanoma cells compared to normal melano-
cytes and between different stages of melanoma progression2, 3. However, in recent years, numerous studies have 
demonstrated that not only genetic and epigenetic changes of neoplastic cells are important to contribute to 
the malignant potential of a tumor but tumor microenvironment plays an important role in determining the 
potential for tumor invasion and metastasis. Cancer associated fibroblasts (CAFs) are one of the principal cell 
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types of the stromal compartment and play a role in tumor cell migration through the stroma4, 5. Tumor cells 
activate CAFs by secreting various cytokines and by undergoing epithelial-mesenchymal transition; CAFs, on 
their side, exert a tumor-promoting function through direct (paracrine soluble factors and cell-to-cell contact) 
and indirect (modulation of other stromal components) approaches6, 7. In epithelial tumors, CAFs help neoplastic 
cells to undergo the epithelial-mesenchymal transition and acquire a phenotype that is optimal for migration 
and invasion at distant sites6, 8, 9 and possibly confers chemoresistance10. Less is known about the function of 
fibroblasts in non-epithelial tumors such as melanoma, but evidence suggests similar roles in tumor develop-
ment and progression. CAFs induced by melanoma cells produce proinflammatory mediators and proteases, 
favor resistance to apoptosis and regulate the anti-tumor response, creating a microenvironment that facilitates 
the proliferation, survival, invasion and metastasis of the tumor11–15. Therefore a bidirectional interdependency 
seems to be fundamental in promoting tumor invasiveness and aggressiveness16 and a multidirectional approach 
is essential when new anti-cancer strategies are planned and developed. The use of RNA sequencing (RNA-seq) 
technology has expanded the diagnostic, prognostic and therapeutic opportunities in cancer research, allowing 
the recognition of gene fusions and differential expression of disease-associated transcripts17, 18. In the melanoma 
field, many studies have focused on RNA-seq of melanocytes19 and melanoma cell lines20–22 and only very recently 
few of them on whole tumor samples or single malignant, immune, stromal and endothelial cells18, 23–26. In vet-
erinary medicine, this technique has been used in recent years to study degenerative diseases and stress-related 
conditions and only rarely has it applied to tumor analysis in canine head and neck carcinoma, mammary car-
cinoma and lymphoma27–30. To the author’s knowledge, no RNA-seq studies have been conducted in veterinary 
medicine to investigate the differentially expressed genes and to elucidate the interactions between neoplastic 
cells and stroma in canine cutaneous melanoma and melanocytoma. The dog is considered a valid model for 
several human cancers31, 32 and for human melanoma because these tumors in dogs share the same locations as 
in humans (skin, mucosal sites, nail matrix and eyes)33, 34. However, despite some similarities, the pathogenesis of 
canine melanoma has not been fully elucidated and the validity of the canine model to study human melanoma 
is still under debate. Regarding the cutaneous tumors, dogs are likely to have different risk factors compared to 
humans, where cutaneous melanomas are mostly UV-induced34. Therefore, the aim of our study was to analyze, 
through RNA-seq analysis, the differential gene expression of canine cutaneous melanocytomas and melanomas. 
Results were validated through qRT-PCR and immunohistochemistry. Due to the importance of the tumoral 
microenvironment and the reciprocal influence between neoplastic and stromal cells, we used RNA extracted 
from formalin-fixed, paraffin-embedded whole primary tumor samples, avoiding the use of cell lines. A total of 
8 cases (4 melanocytomas and 4 melanomas) were retrospectively selected for the purpose of this study. As there 
are no universally accepted criteria to prognosticate canine cutaneous melanocytic neoplasms, for the RNA-seq 
analysis we selected melanomas that had proof of their malignant behavior through the metastatic involvement 
of regional lymph nodes or distant organs. To confirm the results of the RNA-seq, we also investigated the mRNA 
expression of some target genes on a larger series of samples through qRT-PCR. Immunohistochemical analysis 
was used to study the protein expression of two differentially expressed genes. We hypothesized that benign 
melanocytic tumors and malignant tumors and tumors with proven metastatic abilities would show a differen-
tial gene and protein expression pattern and that the genes/proteins involved in the metastatic signature would 
belong to pathways revealing a relationship between neoplastic cells and tumor microenvironment.
Results
Clinical data and histological examination. Data regarding the signalment, location and diagnosis of 
the tumor are summarized in Table 1. The age of affected dogs ranged from 3 to 14 years with an average of 9 
years. Eight cases were females, fifteen were males and for two animals the gender was unknown. Benign tumors 
were mostly located in the eyelid whereas malignant tumors where more commonly located on the distal extrem-
ities and digits. Histological re-examination confirmed the original diagnosis of melanocytomas and melanomas 
in all cases. The amount of stroma in malignant tumors was slightly higher than in benign tumors (mean percent-
age of tumor stroma in melanomas = 26%; mean percentage of tumor stroma in melanocytomas = 20%).
RNA Sequencing and bioinformatic analysis. Sequencing on Illumina platform produced 288 million 
read pairs, distributed as detailed in Supplementary Table S1. The mean number of reads per sample was over 36 
millions. Quality control and trimming procedures retained over the 99% of the produced sequences. Percentage 
of uniquely mapped reads on the reference genome was variable throughout the samples ranging from unaccept-
able quotas around 15% up to 93% of the cleaned sequences. In this step we excluded the two samples that had 
too low mapping statistics (sample n. 4 and n. 5). The low percentage of uniquely mapped reads to the reference 
genome strongly suggested that library preparation was compromised. Indeed, exploratory analysis revealed that 
these 2 samples had to be excluded due to bad clustering and overdispersion of sequence data: the final dataset 
consisted of six libraries (4 melanocytomas – n. 13, 16, 17 and 18 – and 2 melanomas – n. 1 and 6). Uniquely 
mapped reads only (sequences matching only one position throughout the entire genome) were used for the 
differential gene expression assessment to avoid introducing bias through multi-mapper assignment uncertainty. 
After statistical analysis with edgeR, where 11,783 genes were “expressed” (Count per Million >1 in at least half 
the samples), we found 60 differentially expressed genes in melanoma with respect to melanocytoma at a signif-
icance q < 0.05 and absolute fold change (logFC) equal to 1.5. With these filters, 56 genes resulted up-regulated 
(logFC > 1.5) while 4 genes were down-regulated (logFC > −1.5) (Fig. 1 and Supplementary Table S2). After 
annotation of the modulated transcript list through BioMart, the gene names retrieved were used to perform 
enrichment analysis. The annotated list from the differential gene expression analysis was used as input for the 
pathway analysis. The enrichment according to the three biological vocabularies of “Gene Ontology” (Cellular 
Component, Biological Process and Molecular function) was assessed using the tools available on String-DB 
(Search Tool for the Retrieval of Interacting Genes/Proteins). The analysis carried out on the DGE has produced 
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Case Diagnosis Breed
Age 
(Y) Gender Location Metastasis
% stroma 
(% tumor 
area) Examined by
1 Melanoma Mixed 10 M — Regional lymph node 15
RNA-seq, qRT-PCR, 
IHC
2 Melanoma Giant Schnauzer 11 M Digit Popliteal lymph node 45 qRT-PCR, IHC
3 Melanoma Labrador 8 M Digit Popliteal lymph node 30 qRT-PCR, IHC
4 Melanoma Mixed 11 F Perianal Lung 20 RNA-seq, qRT-PCR, IHC
5 Melanoma Mixed 5 M Maxilla Lung, brain 40 RNA-seq, qRT-PCR, IHC
6 Melanoma Dachshund 8 F Abdomen Inguinal lymph node 20
RNA-seq, qRT-PCR, 
IHC
7 Melanoma German Shepherd 8 — Lateral thorax None suspected 15 qRT-PCR, IHC
8 Melanoma Labrador retriever 14 M Digit None suspected 30 IHC
9 Melanoma Rottweiler 11 M Digit None suspected 25 qRT-PCR, IHC
10 Melanoma Miniature pinscher 6 M Limb None suspected 40 qRT-PCR, IHC
11 Melanoma Miniature pinscher 11 F Digit None suspected 25 qRT-PCR, IHC
12 Melanoma Mixed 9 FS Ear None suspected 15 qRT-PCR, IHC
13 Melanocytoma Alaskan husky 13 MC Eyelid None suspected 5 RNA-seq, IHC
14 Melanocytoma Boxer 10 M Eyelid None suspected 15 qRT-PCR
15 Melanocytoma Pinscher 9 FS Muzzle None suspected 40 qRT-PCR, IHC
16 Melanocytoma Pointer — M Eyelid None suspected 10 RNA-seq, qRT-PCR, IHC
17 Melanocytoma Mixed 11 FS Lateral thorax None suspected 5 RNA-seq, qRT-PCR
18 Melanocytoma German Shepherd 9 M Lateral thorax None suspected 20 RNA-seq, qRT-PCR, IHC
19 Melanocytoma Mixed 4 M Chin None suspected 10 qRT-PCR, IHC
20 Melanocytoma Irish setter — — Chest None suspected 20 IHC
21 Melanocytoma Mixed 9 FS Muzzle None suspected 10 qRT-PCR, IHC
22 Melanocytoma Mixed 10 M Eyelid None suspected 20 qRT-PCR, IHC
23 Melanocytoma Giant Schnauzer 10 F Limb None suspected 30 IHC
24 Melanocytoma Golden Retriever 3 M Lip None suspected 35 IHC
25 Melanocytoma German Shepherd 7 M Lip None suspected 40 IHC
Table 1. Tumor location, signalment, percentage of tumor stroma and type of analysis performed in affected dogs.
Figure 1. MA plot showing the relationship between average concentration (logCPM) and fold-change (logFC) 
across the genes. Each gene is represented by a black dot. Significant differentially expressed genes are colored 
in red. The orange dots represent genes in which the counts were zero in all samples of one of the groups. The 
green lines represent logFC +/− 1.5 threshold.
www.nature.com/scientificreports/
4Scientific REPORTS | 7: 6386 | DOI:10.1038/s41598-017-06281-1
a network with large number of highly interconnected genes particularly with experimentally determined inter-
actions (Fig. 2). All the 60 differentially expressed genes had the corresponding protein match (node) leading to 
146 interactions between nodes (edges). The expected value for this subset was 16, way lower than the observed, 
and p-value for these enrichment considering the genomic background resulted to be 0 (Supplementary Table S3, 
Sheet 1). After highlighting the highly interconnected network, we focused on pathways and biological processes 
enriched (FDR < 0.05) with molecules composing the network itself. The significant pathways identified in KEGG 
(Kyoto Encyclopedia of Genes and Genomes: collection of databases that is genomic data, biological pathways, 
diseases, drugs and chemicals questioned by String-DB) involve extracellular-matrix (ECM) interaction, focal 
adhesion, PI3K-Akt signaling pathway, and platelet activation, as detailed in Table 2. The enrichment is even 
more compelling in the three GO vocabularies, using the same set of genes against the annotated human genome 
(Supplementary Table S3, Sheet 4 to 6). For example in the “biological process” section: extracellular matrix 
organization, collagen catabolic process, extracellular matrix disassembly and in the “molecular function” section: 
extracellular matrix structural constituent, metallopeptidase activity and cell adhesion molecule binding.
qRT-PCR. geNorm provides a ranking of the tested genes, considering their expression stability, selecting 
reference genes according to the stability measure M (average pairwise variation of each gene against all others). 
Both HBS2 and GUSβ genes displayed a relatively high stability with M values of 0.4, far below the accepted limit 
of 1.535. THBS2, COL1A1, ADAMTS2 resulted significantly up-regulated in the group of melanomas compared to 
Figure 2. Network of the differentially expressed genes produced by String. Circles are proteins while lines 
are interactions. Known interactions are represented in purple (experimentally determined) and azure (from 
curated databases). Red, green and blue lines pertain predicted interactions (respectively gene neighborhood, 
fusions and co-occurrence) while yellow, indigo and black are interactions found from other sources (text 
mining, co-expression and protein homology). The red halo around gene represents up-regulation while the 
green one down-regulation.
Pathway 
ID Pathway description
Observed 
gene count FDR
4512 ECM-receptor interaction 9 1.22e-09
4974 Protein digestion and absorption 8 1.82e-08
5146 Amoebiasis 8 8.33e-08
4510 Focal adhesion 9 6.27e-07
4151 PI3K-Akt signaling pathway 10 2.22e-06
4611 Platelet activation 7 4.1e-06
Table 2. Significantly enriched KEGG pathways according to StringDB.
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melanocytomas (P < 0.05, Mann–Whitney). COL11A1 and NOS2, although slightly unregulated, did not show a 
statistically significant difference between the two groups of tumors (Fig. 3).
Immunohistochemical examination. Cytoplasmic reactivity for COL1 was observed both in neoplastic 
and stromal cells in melanomas and melanocytomas, whereas THBS2 was expressed only by neoplastic cells 
(Fig. 4). The average percentage of positive cells for COL1 was 86.67% in melanomas and 72.73% in melanocy-
tomas (P = 0.08), whereas for THBS2 was 64.17% in melanomas and 54.27% in melanocytomas (P = 0.44). No 
statistically significant differences were noted between the two groups in terms of percentage of positive cells, 
intensity of immunoreactivity, pattern of reaction and distribution of reactivity.
Figure 3. Bar charts representing relative expression values of COL1A1, THBS2, ADAMTS2, NOS2 and COL11 
genes in melanocytomas (blue) and melanoma (green) on a base 2 logarithmic scale. Whiskers define a 95% CI 
(confidence interval). Statistical significance is evidenced with asterisks and relative p-value.
Figure 4. Immunohistochemical expression of COL1 and THBS2 in melanocytic tumors. (A) Cytoplasmic 
positivity for COL1 in numerous neoplastic cells and fewer stromal cells in a melanoma; (B) occasional COL1 
positive cells in melanocytoma; (C) diffuse cytoplasmic stain for THBS2 in an amelanotic melanoma; (D) 
scattered and mild THBS2 positivity in melanocytoma cells.
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Discussion
Our RNA-seq analysis study confirmed the presence of differentially expressed genes in canine cutaneous mel-
anocytomas and melanomas. The differentially expressed genes belong to the PI3K-Akt activation pathway that 
has already been demonstrated to be activated in human and canine melanomas36–38. The KEEG pathway analysis 
revealed a link between the PI3K-Akt pathways and the extracellular environment were the focal adhesion and 
the ECM pathways are upstream regulators of the PI3K-Akt (Fig. 5). Our results also suggest the activation of 
newly detected genes involved in the ECM-cell interaction pathway that have not yet identified in human mel-
anoma expression studies. The RNA-seq approach has been uncommonly used to study human melanoma cell 
lines18, 21, 39 and only single studies have examined human primary and metastatic melanoma tumor samples23. 
Numerous authors have demonstrated a reciprocal effect of host-tumor interactions on neoplastic and stromal 
cells and a synergistic effect of co-cultivation of human melanoma and stromal fibroblasts in invasive and met-
astatic abilities11, 16, 40–42. These results have substantiated the observation that data obtained from studies based 
on melanoma cell lines and melanocyte cultures may not always be applicable to melanocytic tumors and their 
in vivo biology. Therefore, our goal was to investigate the whole neoplastic tissue, avoiding the use of cell cul-
tures, in order to explore the interactions between cancer cells and stromal components in canine melanocytic 
tumors. To our knowledge, no similar approach has been used on canine tissues. In a previous experiment, we 
attempted at extracting RNA from lentigo (melanocytic hyperplasia) lesions from 4 dogs that would have served 
as normal melanocyte control. However, the yield of RNA was insufficient for further analysis and therefore 
our study focused on the differential expressed genes in benign (melanocytomas) and malignant (melanomas) 
tumors. The inclusion criteria for the latter in the RNA-seq was that the melanomas must have had proof of 
metastatic behavior through a histologically confirmed lymph node metastasis or systemic dissemination, since 
the currently used histologic criteria are partially insufficient to predict the prognosis of canine cutaneous mel-
anomas43. The comparison of gene expression profiling between metastatic melanoma and melanocytoma cases 
identified 60 genes with a differential expression: 56 genes were up-regulated and 4 were down-regulated. The 
difference in gene expression was almost always more than two logFC compared to the melanocytoma group. This 
strong difference suggests an activation of differential pathways associated with cancer progression in melano-
mas. The enriched pathway analysis revealed that the differentially expressed genes involve genes regulating cell 
survival and proliferation and in particular the PI3K-Akt pathway. Our results are similar to studies conducted 
on canine melanoma tumors and melanoma cells lines which have demonstrated that the PI3K-Akt pathway is 
dysregulated in the dog, with expression patterns similar to human melanomas44, 45. On the contrary, BRAF and 
NRAS mutations appear to be uncommon in canine melanomas34, 44, 46–48 and our results, although based on gene 
expression profiling, let us speculate that mutations activating these genes are indeed rare in canine cutaneous 
melanoma. In addition to the PI3K-Akt pathway, the gene expression analysis of our case series demonstrated 
a strong upregulation of ECM-receptor interaction pathway in melanomas compared to melanocytomas. Many 
of the genes involved are indeed upstream regulators of the PI3K-Akt pathway, through the link of focal adhe-
sion family proteins, such as integrins. The upregulation of this pathway is also supported by the differentially 
expressed NOS2 (nitric oxide synthase 2, inducible NOS – iNOS). NOS2 has been demonstrated to favor the 
metastatic potential of melanoma, either directly modulating tumor cell metabolism49 and driving survival and 
Figure 5. The extended Kegg Pathway for PI3K-Akt signaling. Genes activating the ECM-receptor interaction 
pathway and upstream of the PI3K-Akt molecule are depicted in the rectangle. The genes that were differentially 
expressed in this study are bold face and red colored.
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proliferation of human melanoma cells50 or indirectly through the activation of pro-tumorigenic γδ T cells51. Our 
results are further supported by a very recent study which demonstrates that human melanoma cells co-cultured 
in the presence of fibroblasts undergo a phenotype switch toward mesenchymal-like cells, activate the PI3K-Akt/
mTOR signaling pathway and become resistant to the BRAF inhibitor vemurafenib52. Our study also reveals an 
overexpression of fibronectin type III domain, a mechanically sensitive protein forming interacting fibrils in the 
extracellular matrix. This finding is in accordance with a study by Cho and colleagues that elegantly demonstrates 
that fibronectin type III domain is able to induce resistance to apoptosis in human lung cancer cells, through the 
activation of the PI3K-Akt/αvβ5 signaling axis53. ADAMTS2 (a disintegrin and metalloproteinase with throm-
bospondin type 1 motif 2) was overexpressed in melanomas, compared to melanocytomas. Giricz et al. demon-
strated an overexpression of ADAMTS2 in melanoma tissues of affected individuals compared to normal tissue of 
the same patients54. In the same study, the expression of this gene was also investigated in metastatic melanoma 
cell lines compared to cultured fibroblasts and was found to be higher in fibroblasts compared to metastastic 
melanoma cells. This would be consistent with its role in pro-collagen processing. Therefore, we suggest that 
the ECM-receptor interaction pathway could represent an alternative pathway contributing to the downstream 
activation of PI3K-Akt in canine cutaneous melanomas. To further confirm our results, a qRT-PCR analysis was 
performed on a larger series of samples of melanomas and melanocytomas. A statistically significant difference 
between melanomas and melanocytomas was observed for COL1A1, THBS2 and ADAMTS2. Although slightly 
up-regulated in melanomas, COL11A1 and NOS2 did not show a statistically significant difference. This could 
be due to the low number of samples or to the high individual variability. The immunohistochemical protein 
expression analysis could be performed on COL1 and THBS2 only due to the unavailability of specific anti-canine 
antibodies for FFPE tissues. The results of this analysis revealed a higher expression of both markers in melano-
mas compared to melanocytomas, yet the difference was not statistically significant. As immunohistochemistry 
is not a quantitative technique and is less sensitive than PCR, the low number of samples could have impacted on 
the significance of the results.
No ECM/collagen pathway activation has ever been demonstrated before in melanomas, despite numerous 
ECM-related genes have been associated with poor clinical outcomes in several types of cancer55–59. In primary 
human breast carcinomas, different sets of ECM-related genes have been confirmed to have an impact on the 
clinical outcome of the tumor60. However, no differences in the expression of their corresponding products were 
noted in the same study and no correlation was found between the differentially expressed EMC genes and dif-
ferent features of the stroma. This can be due to post-translational modifications of ECM components61 or to 
the need for specific spatial distribution of mutually interacting compounds that is necessary for the activation 
of EMC related enzymes62. In this view, in recent years a new concept has emerged regarding the “matrisome”, 
defined as the ensemble of genes encoding ECM and ECM-associated proteins, as a tool to better characterize the 
ECM composition, metabolism and biology in order to gain new insight on prognostic and diagnostic markers 
and therapeutic opportunities63. Among the extracellular matrix-receptor interaction pathway, several collagen 
genes were upregulated in malignant melanomas compared to melanocytomas; one of the most upregulated 
was COL11A. A collagen-remodeling gene signature has been found in human ovarian cancers, where levels of 
COL11A1 continuously increase during disease progression, with the highest expression in recurrent metas-
tases59. In the same study, other genes such as COL5A1, periostin (POSTN), thrombospodin 2 (THBS2) and 
LOX were upregulated and associated with poor survival after adjuvant chemotherapy; these genes were also 
upregulated in our melanoma case series. Another study found that the expression of COL11A1 and COL5A2 
genes in colorectal cancers is correlated with carcinoma aggressiveness and progression, as well as lymph node 
metastasis, and that these genes are not expressed in normal colon samples64. COL11A1 has also been found 
to be expressed at the front of invasive carcinomas by presumably carcinoma cells, putatively undergoing 
epithelial-to-mesenchymal (EMT) transition; also, carcinoma-derived cells with highly metastatic capabilities 
can express COL11A165. To the author’s knowledge, there are no studies investigating or demonstrating the role of 
COL11A1 in melanomas, neither in human nor veterinary literature; however, as molecular equivalents of EMT 
have been demonstrated in human melanomas as well66, it is reasonable to think that a similar process involving 
COL11A1 is taking place in melanoma. In deeply invasive human cutaneous melanomas, COL1 mRNA was found 
to be strongly expressed in stromal cells close to and encircling melanoma nests in the papillary dermis, whereas 
this expression was not noted in the deep fibroblasts in the reticular dermis, demonstrating the presence of two 
different microenvironments in cutaneous melanomas. Inhibition of COL1 expression before tumor develop-
ment in an experimental porcine model decreased the invasivity of the tumors by decreasing the number of 
tumor-associated blood vessels, without affecting melanoma cell proliferation67, 68. Therefore, COL1 expression 
by tumor associated fibroblasts can have a proangiogenic effect, where COL1 can be important for supporting 
and guiding the developing endothelial cells. In our study, we did not investigate the tumor vasculature. However, 
COL1A1 and COL1A2 were both strongly overexpressed in the melanomas compared to melanocytomas, in 
agreement with the study from Van Kempen. Furthermore, collagen type I and type III have been demonstrated 
to be able to down-regulate the expression of E-cadherin in pancreatic cancer cell lines69 and it is known that the 
down-regulation of E cadherin is an important step in melanoma progression66. In our immunohistochemical 
analysis, COL1 expression was found not only in fibroblasts of the stroma of the tumor but also in the neo-
plastic cells. Therefore, collagen production by neoplastic cells could favor E cadherin down-regulation and the 
epithelial-to-mesenchymal transition. Our study also showed an overexpression of thrombospondin-2 in mela-
nomas compared to melanocytomas. Thrombospondin-2 is considered a potent endogenous inhibitor of tumor 
growth and angiogenesis70. This molecule has also been proven to suppress hematogenous metastasis in human 
malignant melanoma cell lines through microenvironment-modifications such as increase of the PA (plasmino-
gen activator) inhibitors and decrease of the vascularity of metastatic lesions71. However, other studies demon-
strated a differential expression of this molecule between melanoma metastases and primary tumors, suggesting 
that the modulation of cell-matrix interactions is pivotal in the pathogenesis of malignant melanoma metastasis72. 
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Differences in these results could be explained by mechanisms causing a rapid degradation of mRNA or block-
ing its translation into a protein or by the instability of the protein, which appears to be very unstable once it is 
secreted, as is the case for the other members of the thrombospondin family73. Worthy of note is also the upregu-
lation of LOX in our malignant melanoma samples. The LOX family proteins have been long known to modulate 
extracellular matrix molecules, promoting a migratory, highly invasive and metastatic phenotype in human breast 
cancer cell lines as well as in rat prostatic cell lines and human cutaneous melanoma cell lines74. In the same study, 
endogenous LOX mRNA expression could be induced in poorly invasive breast cancer cell lines by cultivating 
cells in the presence of fibroblasts-conditioned medium or matrix, suggesting a role for stromal fibroblast in LOX 
regulation. Furthermore, LOX proteins have also been shown to have intracellular functions such as direct or 
indirect Snail activation, the latter mediated by hypoxia-inducible factor 1alpha (HIF-1alpha) recruitment74, 75. By 
comparing the morphological features (hematoxylin and eosin, H&E) of our samples, the melanomas were char-
acterized by a slightly more prominent stroma than the melanocytomas. Therefore, we cannot exclude that the 
differential expression of collagen and ECM genes found in our study is due to a different tumor-to-stroma ratio 
and to a difference in the amount of collagen tissue between the two groups. However, the difference between the 
two groups was not marked and, due to the same tissue origin (skin) for both sample groups, the more abundant 
connective tissue in melanomas is considered as a melanoma-related effect. The stroma, in response to signals 
most likely originating from transformed cells, can be therefore indirectly responsible for the generation of a 
microenvironment that is promoting cell-matrix interactions and connective tissue remodeling, thereby facil-
itating a prometastatic environment. The identification of collagen-remodeling genes as a metastatic and poor 
prognosis gene signature suggests that collagen remodeling might be a common biologic process that contributes 
to poor overall survival (OS) among dogs with cutaneous melanomas. Our RNA-seq experiment was done on a 
small case series, due to the rarity of canine cutaneous melanomas with proven malignant behavior. A larger scale 
study with a higher number of metastatic tumors would be worthy. Finally, in our study we used FFPE samples: 
this treatment is known to produce bias, as we directly observe in some of our libraries and probably affecting 
low expressed genes due to high rate of RNA degradation. However, studies have been conducted76 proving that 
results on FFPE samples correlated with the one obtained with fresh tissue with some caveats.
In conclusion, in the present study, we characterized the transcriptome of melanoma vs melanocytoma sam-
ples, with cutting edge techniques, in the canine model species where no such data are available. The RNA-seq 
data were confirmed with qRT-PCR and immunohistochemistry. Novel is also the choice of whole paraffin sec-
tions instead of tumor cell primary cultures, which is considered more representative of the tumor biology in 
vivo and of the interactions between tumor cells and stroma. This study shows that gene expression levels in 
melanomas were different from melanocytomas, indicating an association with malignancy. The analysis of dis-
ease process categories showed that canine melanoma shares activation of similar molecular pathways as human 
melanoma, such as PI3K-Akt. However, most likely this pathway is activated by different upstream mechanisms, 
such as a strong upregulation of genes involved in collagen and extracellular matrix metabolism, organization and 
remodeling. We hypothesize that the developing melanoma actively promotes collagen metabolism, extracellular 
matrix remodeling, cell proliferation and survival mechanisms contributing to disease progression and metas-
tasis. In order to define the biological and clinical significance of our findings, detailed molecular mechanistic 
studies are needed to determine the causal relationships of the differentially expressed genes and oncogenesis. 
These findings would support further investigations on the utility of therapeutic targeting of ECM-cell matrix 
interaction pathways in canine melanoma treatment. Finally, in this study, we also detect genes not yet identified 
in human melanoma expression studies. Comparative studies could then explore the translational potential of 
such approach for the treatment of the human disease.
Methods
Samples. Twelve formalin-fixed, paraffin-embedded (FFPE) samples (6 melanocytomas and 6 melanomas) 
were selected from the archives of our Departments. Samples had been trimmed and processed according to 
current recommended guidelines77. Melanoma samples that were submitted to RNA seq were chosen between the 
tumors that had proof of metastatic behavior (histologically confirmed lymph node metastasis/distant metastasis).
Histological examination. Sections (4 μm thick) were cut from the paraffin blocks and stained with H&E. 
The tumors were evaluated blindly and independently by three experienced pathologists (CB, IP, MS). Tumors 
were reclassified using histologic parameters with the most statistically supported validity for prognostic use in 
canine melanocytic neoplasia, according to the recent classification43, 78–80. According to these criteria, all tumors 
that had concomitant lymph node/distant metastases had been correctly classified as malignant (“melanoma”). 
The three pathologists empirically calculated the ratio between stroma and tumor, considering the area repre-
sented by stromal tissue on the whole tumor mass and assigning it a percentage value.
RNA extraction. RNA extraction was performed from four to six, 8 µm-thick paraffin sections with a com-
mercial kit following the manufacturer’s instructions (RecoverAll Total Nucleic Acid Isolation Kit, AM 1975, 
Ambion, Austin, Texas). Residual genomic DNA was removed from the total RNA by DNAse treatment, which 
was included in the commercial kit. Normal tissue located at the tumor margins was carefully resected and dis-
carded with the help of a scalpel blade or a sterile needle during the paraffin sectioning procedure. RNA quantity 
and quality were evaluated using NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA, 
USA) and Qubit 2.0 Flurometer (Life Technologies, MA, USA), while RNA integrity was assessed by microfluidic 
electrophoresis on BioAnalyzer 2100 (Agilent Technologies).
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RNA sequencing. FFPE samples suitable for library preparation according to quality/quantity evaluation, were 
processed concurrently and following the manufacturer’s specifications with the Illumina TruSeq Stranded Total RNA 
(Ribozero) ver. 3 for a total of 8 samples, 4 derived from melanoma and 4 from melanocytoma cases. After rRNA deple-
tion the samples were not fragmented because the RNA Integrity Number of starting material was very low. Massive 
parallel sequencing was carried out on an Illumina HiSeq 1500 machine generating 101 bases paired-end reads.
Bioinformatic analysis. RAW sequences from the sequencer were checked for quality control and trimmed 
from adapters using FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc) and Trimmomatic v. 
0.3381, respectively. After this step, the resulted paired reads were mapped using STAR v.2.4.0.182 with default 
parameters, guided by the Ensembl v.84 transcript annotation downloaded from the UCSC Table browser, on the 
Canis familiaris reference genome (CanFam3.1). Common quality parameters in RNA-seq experiments (insert 
length, gene mapping bias, RNA junctions) were evaluated using RSeQC83. To account for differential expression 
between the groups, a count based approach using uniquely mapped reads only was used: aligned reads were 
classified as counts on genes with the software featureCounts using the Ensembl 84 annotation coordinates84 
and gene expression changes identified using edgeR85. EdgeR package uses the negative binomial distribution as 
a model to analyse the differential gene expression from RNA-seq data between conditions, accepting as input a 
matrix with the raw counts number for each sample and each annotated feature. Briefly, a matrix were rows rep-
resented the Ensembl gene annotation and columns represented the sample was imported into R and differential 
gene expression was assessed following best practices for the edgeR package. A gene was considered differentially 
expressed if the False Discovery Rate (FDR) adjusted p-value (q-value) was lower than 0.05 and log Fold Change 
comprised between −1.5 and +1.5. Differentially expressed genes between two groups were annotated using 
BioMart (http://www.ensembl.org/biomart/martview/).
Enrichment analysis. Different approaches were applied to search for enriched Gene Ontology (GO) terms 
and pathways. The differentially expressed gene list was used as input for STRING DB R Package86. STRING (http://
www.string-db.org) is a database of known and predicted protein-protein interactions. The interactions include 
direct (physical) and indirect (functional) associations. The database collates information from different sources 
ranging from experimental evidences to library mining interactions providing confidence scores for each interaction.
qRT-PCR assays. Total RNA (250 ng) of each sample was reverse transcribed in triplicate using the 
SuperScript® VILO™ Master Mix (Thermofisher), according to the manufacturer’s specifications and succes-
sively put together in a single aliquot. Successful reverse transcription was confirmed by PCR amplification of 
the Canis familiaris GUSβ gene (NM_001003191). Primers on reference genes (GUSβ, HMBS) and on genes of 
interest (THBS2, COL1A1, COL11A1, NOS2, ADAMTS2) were designed based on available sequences using the 
Primer-BLAST suite (details in Supplementary Table S4). Whenever possible, primers were located in different 
exons or at an exon–exon junctions to minimize inaccuracies due to genomic DNA contamination. For each 
primer pair, a preliminary qRT-PCR assay, on a bulk of samples, was performed to check for amplification of 
non-specific products or primer-dimer artifacts and efficiency (E) were assessed. The qRT-PCR reaction was 
carried out aliquoting 5 μl of a five-fold diluted cDNA and SsoFast™ EvaGreen® Supermix (BioRad). The ampli-
fication was performed in a CFX96 Touch instrument (BioRad, Hercules, CA) with the following conditions: 
98 °C for 3 min, then 50 cycles of 98 °C for 10 s and 60 °C for 15″. Fluorescence data were collected at the end of the 
second step and, following cycling, the melting curve was determined in the range of 58–95 °C with an increment 
of 0.01 °C/sec. Each reaction was run in triplicate with appropriate negative controls.
Data analyses. Data analysis was carried out with Bio-Rad CFX Manager software (ver. 3.2.2) and GenEx 
(ver.6). To analyze gene expression stability of HKGs, geNorm algorithm, included on CFX Manager software (ver. 
3.2.2), was used35. The expression ratio of the genes of interest was normalized relative to the abundance of the two 
reference genes (HBS2, GUSβ) using the ΔΔCq method. Samples were divided in two groups, melanomas (MM) 
and melanocytomas (MCT) and were tested for parametric data distribution using the Kolmogorov-Smirnov 
(KS) Test. Changes in the relative gene expression between groups were calculated using Mann-Whitney Test for 
unpaired data, because the data were not-normally distributed. All expression values are presented as means in a 
base 2 logarithmic scale with a confidence interval of 95%.
Immunohistochemical examination. For immunohistochemical analysis, paraffin blocks were 
cut into sections of 5 µm thickness, mounted on positively charged slides, dewaxed and rehydrated. 
Immunohistochemistry was performed using rabbit polyclonal antibodies against Collagen 1 (COL1, Biorbyt, 
San Francisco, CA) and Thrombospondin 2 (THBS2, Biorbyt, San Francisco, CA). Antigen retrieval was per-
formed in a microwave oven with citrate buffer (pH 6.0). Blocking of endogenous peroxidase with 3% H2O2 
solution for 10 minutes at room temperature was performed. Primary antibodies were incubated overnight at 
4 °C (dilution 1:100 for COL1; 1:200 for THBS2). Then, slides were treated with a ready-to-use kit (Mouse and 
Rabbit Specific HRP; Abcam, Cambridge, UK) following the manufacturer’s instructions. Positive reactions were 
revealed with 3-amino-9-ethilcarbazole (AEC Substrate; Abcam, Cambridge, UK). Positive cells were blindly 
evaluated by two operators (CB, IP) on the total tumoral section and assigned a percentage value (0–100% repre-
senting the percentage of positive neoplastic cells on the total number of neoplastic cells), an intensity (1 = mild, 
2 = moderate, 3 = marked), a pattern (peripheral, diffuse, random) and distribution (focal, multifocal, diffuse). 
Differences between groups were evaluated with a two tailed Student t-test for non paired samples. All statistical 
calculations were performed using R base statistical package. A p value lower than 0.05 was set as threshold for 
statistical significance. Other proteins corresponding to the target genes of the qRT-PCR could not be analysed, 
due to the unavailability of specific anti-canine antibodies for formalin-fixed, paraffin-embedded samples.
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